{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:58Z","timestamp":1788225358215,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473324"],"award-info":[{"award-number":["82473324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172730"],"award-info":[{"award-number":["82172730"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373285"],"award-info":[{"award-number":["82373285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2021YFA0909800"],"award-info":[{"award-number":["2021YFA0909800"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022B1515020056"],"award-info":[{"award-number":["2022B1515020056"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024A1515010317"],"award-info":[{"award-number":["2024A1515010317"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.isci.2026.116353","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:02Z","timestamp":1781632442000},"page":"116353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Xiaoting","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7152-0965","authenticated-orcid":false,"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116353_bib1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116353_bib2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116353_bib3","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116353_bib4","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1002\/cam4.3437","article-title":"Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels","volume":"9","author":"Khorana","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.isci.2026.116353_bib5","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1634\/theoncologist.2015-0361","article-title":"A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality","volume":"21","author":"Kuderer","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.116353_bib6","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2022.01.004","article-title":"Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies","volume":"213","author":"Moik","year":"2022","journal-title":"Thromb. Res."},{"key":"10.1016\/j.isci.2026.116353_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101354","article-title":"Treatment modalities in cancer-associated venous thromboembolism (VTE)","volume":"35","author":"Soto Alsar","year":"2022","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.isci.2026.116353_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2125.2003.01904.x","article-title":"Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction","volume":"56","author":"Bruno","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.isci.2026.116353_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)80058-6","article-title":"A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 Entry","volume":"99","author":"Shukla","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116353_bib10","doi-asserted-by":"crossref","first-page":"16026","DOI":"10.1073\/pnas.1110617108","article-title":"Heparan sulfate binding by natural eastern equine encephalitis viruses promotes neurovirulence","volume":"108","author":"Gardner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116353_bib11","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1128\/JVI.03116-13","article-title":"A Single-Amino-Acid Polymorphism in Chikungunya Virus E2 Glycoprotein Influences Glycosaminoglycan Utilization","volume":"88","author":"Silva","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.116353_bib13","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116353_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.isci.2026.116353_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/2159-8290.CD-NB2015-158","article-title":"First Oncolytic Viral Therapy for Melanoma","volume":"6","author":"Poh","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116353_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.coviro.2015.03.020","article-title":"Oncolytic viruses: perspectives on clinical development","volume":"13","author":"Burke","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib17","doi-asserted-by":"crossref","first-page":"E4504","DOI":"10.1073\/pnas.1408759111","article-title":"Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116353_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03285-0","article-title":"Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.116353_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","article-title":"Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.isci.2026.116353_bib20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116353_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.isci.2026.116353_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.isci.2026.116353_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33661-7","article-title":"Bottom-up assembly of viral replication cycles","volume":"13","author":"Staufer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116353_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105476","article-title":"The life cycle of the alphaviruses : From an antiviral perspective","volume":"209","author":"Skidmore","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2026.116353_bib25","article-title":"Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumors","volume":"7","author":"Song","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.isci.2026.116353_bib26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.5414\/CP204022","article-title":"Bioavailability study of Enoxaparin Sodium Chemi (80 mg\/0.8 mL) and Clexane (80 mg\/0.8 mL) subcutaneous injection in healthy adults","volume":"59","author":"Febbraro","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.isci.2026.116353_bib27","series-title":"StatPearls","article-title":"Steady State Concentration","author":"Wadhwa","year":"2026"},{"key":"10.1016\/j.isci.2026.116353_bib28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.isci.2026.116353_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.23736\/S0392-9590.19.04110-5","article-title":"Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database","volume":"38","author":"Fuentes","year":"2019","journal-title":"Int. Angiol."},{"key":"10.1016\/j.isci.2026.116353_bib30","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1002\/onco.13596","article-title":"Update on Guidelines for the Management of Cancer-Associated Thrombosis","volume":"26","author":"Streiff","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.116353_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.isci.2026.116353_bib32","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1128\/jvi.70.6.3461-3469.1996","article-title":"Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry","volume":"70","author":"Herold","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.antiviral.2016.12.023","article-title":"Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells","volume":"140","author":"Ghezzi","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.isci.2026.116353_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/biomedicines10010049","article-title":"Enoxaparin and Pentosan Polysulfate Bind to the SARS-CoV-2 Spike Protein and Human ACE2 Receptor, Inhibiting Vero Cell Infection","volume":"10","author":"Ennemoser","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2026.116353_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01987-20","article-title":"Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives","volume":"95","author":"Tandon","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib36","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1128\/JVI.75.18.8772-8780.2001","article-title":"Heparan Sulfate Glycosaminoglycans Are Receptors Sufficient To Mediate the Initial Binding of Adenovirus Types 2 and 5","volume":"75","author":"Dechecchi","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib37","doi-asserted-by":"crossref","first-page":"10075","DOI":"10.3390\/ijms221810075","article-title":"Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses","volume":"22","author":"Mese","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.116353_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14573-9","article-title":"Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus","volume":"7","author":"Choijilsuren","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.116353_bib39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: a fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116353_bib40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN-\u03b1 subtypes: distinct biological activities in anti-viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.isci.2026.116353_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral Actions of Interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.isci.2026.116353_bib42","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00841-19","article-title":"Distinct Roles of Interferon Alpha and Beta in Controlling Chikungunya Virus Replication and Modulating Neutrophil-Mediated Inflammation","volume":"94","author":"Cook","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.116353_bib44","article-title":"Innate immune evasion by alphaviruses","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226017281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226017281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:00:40Z","timestamp":1788224440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226017281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589004226017281"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116353","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical dose of enoxaparin enhances oncolytic virus M1 infection and antitumor efficacy in human bladder cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116353"}}